Format

Send to

Choose Destination
Blood Adv. 2019 Sep 10;3(17):2598-2603. doi: 10.1182/bloodadvances.2018021295.

Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia.

Author information

1
Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH.
2
Division of Hematology and Oncology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA.
3
Penn State Hershey Cancer Institute, Hershey, PA.
4
Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA.
5
Department of Pharmacology, University of Virginia School of Medicine, Charlottesville, VA.
6
Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
7
Division of Hematology and Oncology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA.
8
University of Virginia Cancer Center, Charlottesville, VA.
9
Nanotechnology Characterization Laboratory, Advanced Technology Program, SAIC-Frederick, Inc., National Cancer Institute-Frederick National Laboratory for Cancer Research, Frederick, MD.
10
Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA.
11
Human Oncology and Pathogenesis Program, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
12
Pediatric Molecular Oncology Program, Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA; and.
13
nanoSTAR Institute, University of Virginia, Charlottesville, VA.

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center